India's Health Ministry Restricts Stem Cell Therapy for Autism to Approved Clinical Trials
核心洞察
The Union Health Ministry issued a 16 September 2026 advisory barring stem cell therapy as standard care outside indications approved by the Ministry.
The advisory implements a January 2026 Supreme Court ruling that unapproved stem cell therapy cannot be offered as routine or commercial treatment for autism.
Stem cell use in autism must remain confined to duly approved clinical trials under the National Guidelines for Stem Cell Research, 2017.
India's Ministry of Health & Family Welfare (搜索) has issued an advisory dated 16 September 2026 directing all States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010 to enforce existing restrictions on stem cell therapy, including a prohibition on its routine use for Autism Spectrum Disorder (搜索) (ASD).
The advisory follows the Supreme Court's judgment of 30 January 2026 in Yash Charitable Trust (搜索) & Ors. v. Union of India & Ors., W.P. (C) No. 369 of 2022 [2026 INSC 96]. Hearing a public interest litigation filed by the Yash Charitable Trust, a two-judge bench comprising Justice J.B. Pardiwala and Justice R. Mahadevan ruled that patients have no "fundamental or statutory right to demand experimental treatment outside the regulatory framework."
Autism Use Confined to Approved Trials
The Ministry's advisory reiterates the existing framework governing stem cell research and therapy and seeks to ensure that stem cell therapy is permitted as standard care in routine clinical practice only for disease conditions and indications included in the list approved by the Ministry of Health & Family Welfare (搜索).
Specifically for ASD, the advisory stipulates that the therapeutic use of any type of stem cell in autism is to remain restricted to duly approved clinical trials, in accordance with the National Guidelines for Stem Cell Research, 2017, issued jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (搜索) (DBT), along with other applicable Government of India instructions issued from time to time.
The Ministry has asked States and Union Territories to widely disseminate the Supreme Court's directions to all concerned State and District Regulatory Authorities and to government and private clinical establishments involved in stem cell research, treatment, promotion or administration, for strict compliance with the applicable framework.
Enforcement and Consequences of Non-Compliance
The advisory draws attention to the consequences of non-compliance. In Para 151(xiii) of its 30 January 2026 judgment, the Supreme Court held that non-compliance with the statutory mandate must attract consequences, including professional misconduct under Regulation 7.22 of the IMC Regulations, 2002, as well as action under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010, which provide for cancellation of registration and penalty.
Reinforcing the regulatory position, the National Medical Commission (搜索) (NMC), in an advisory dated 5 September 2026, reiterated that stem cell therapy may be offered as standard clinical care only for approved indications. The NMC stated that unauthorised administration, prescription, promotion or advertisement of stem cell therapy beyond the approved indications would constitute professional misconduct. The NMC further advised State Medical Councils to examine cases of alleged violations brought to their notice and, where professional misconduct by a Registered Medical Practitioner is established after due process, to take appropriate disciplinary action in accordance with applicable statutory and regulatory provisions.
The Ministry has accordingly requested the concerned State and District Regulatory Authorities and clinical establishments to ensure strict compliance with the applicable framework governing stem cell research and therapy.
Regulatory Directions and the Approved CAR-T Landscape
In its order, the Supreme Court directed the government to strengthen regulatory frameworks and ensure that patients currently undergoing unverified therapies are safely shifted to legitimate clinical trials. It also called for establishing a dedicated national authority to regulate such therapies.
Stem cell therapy is a type of regenerative medicine that uses the body's master cells to repair damaged tissues or replace diseased cells. In India, the field is governed by the 2017 ICMR-DBT guidelines along with other instructions issued by regulators over time. The central licensing authority, CDSCO (搜索), has so far approved two CAR-T cell therapies — NexCAR19, developed by ImmunoACT (搜索), and Qartemi (搜索), of Immuneel Therapeutics (搜索) — for treating blood cancer patients who have exhausted other treatment options.